Opinion statement
NSCLC is the leading cause of cancer mortality in the United States. Approximately 30–40% of patients present with advanced stage disease (Stage IIIb with malignant effusion and Stage IV) and the majority of those who present with “earlier” disease will ultimately develop and succumb to metastatic lung cancer. Although platinum-based combination chemotherapy has been shown to impact overall survival and quality of life, it is not curative and less than 25% of patients survive 2 years. Therefore, the benefits of chemotherapy must be weighed against toxicity, inconvenience, and cost. Several randomized trials have shown that there is no added benefit of extending first line, platinum-based chemotherapy beyond four cycles. There was no additional survival benefit and patients experienced increased toxicity with longer durations of therapy. Attempts to improve outcome by planned sequential therapy, i.e. shifting from one cytotoxic regimen to another after a fixed number of cycles have also not been successful. Several new so-called “targeted” therapeutic agents have recently been evaluated in clinical trials to assess whether the efficacy of first line chemotherapy with platinum doublets can be improved with the addition of these agents. These include bevacizumab, epidermal growth factor receptor inhibitors (erlotinib and gefitinib), bexarotene, matrix metalloproteinase inhibitors, and others. Other than bevacizumab, none have demonstrated benefit in this scenario. The design of most of these trials employed the concurrent use of the new agent with six cycles of platinum-based chemotherapy (usually either carboplatin/paclitaxel or cisplatin/gemcitabine) and then continued the new agent until relapse. Three agents have demonstrated benefit in randomized studies in the second line setting, docetaxel, pemetrexed, and erlotinib. No study has evaluated the optimal duration of therapy for these agents, though for erlotinib, it appears that use until progression is optimal. Future studies of novel agents will need to explore not only the potential use of these agents in combination or in comparison with standard therapy, but also the duration of therapy and consider issues of survival, quality of life, and cost.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Cullen MH, Billingham LJ, Woodroffe CM, et al (1999) Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life. J Clin Oncol 17:3188–3194
Anonymous: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials—Non-small Cell Lung Cancer Collaborative Group. BMJ 1995, 311:899–909.
Wozniak AJ, Crowley JJ, Balcerzak SP, et al (2001) Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 16:2459–2465.
Sandler AB, Nemunaitis J, Denham C, et al (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122–130
D’Addario G, Pintilie M, Leighl N, Feld R, Cerny T, Shepherd FA (2005) Platinum –based versus non-platinum based chemotherapy in advanced non-small cell lung cancer: A meta-analysis of the published literature. J Clin Oncol 23:2926–2936
American Society of Clinical Oncology (1997) Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 15:2996–3018
Buccheri GF, Ferrigno D, Curcia A, et al. (1989) Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study. Cancer 63(3):428–432
Pfister DG, Johnson DH, Azzoli CG, et al. (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22(2):330–353
Smith IE, O’Brien ME, Talbot DC, et al. (2001) Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 19(5):1336–1343
Socinski M, Schell M, Peterman A, et al. (2002) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second line therapy in advanced stage IIIB/IV non-small cell lung cancer. J Clin Oncol 20:1335–1343
von Plessen C, Bergman B, Andresen O, et al. (2006) Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 95(8):966–973
Edelman MJ, Clark J, Chansky K, Albain K, Gandara DR. (2004) Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer: Carboplatin/Gemcitabine followed by Paclitaxel or Cisplatin/Vinorelbine followed by Docetaxel (SWOG 9806). Clin Cancer Res 10(16):5418–5424
Binder D, Schweisfurth H, Grah C, et al.: Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial. Cancer Chemother Pharmacol. 2006 Oct 10; (Epub ahead of prin).
DePierre A, Quiox E, Mercier M, Breton J, Moro-Sibilot D, Debeiuvre D. (2001) Maintenance chemotherapy in advanced non-small cell lung cancer: A randomized trial of vinorelbine versus observation in patients responding to induction chemotherapy. Proc Am Soc Clin Oncol 20:309a
Johnson DH, Fehrenbacher L, Novotny WF, et al. (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184–2191
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer. N Engl J Med 355:2542–2550
Ratain MJ, Eisen T, Stadler WM, et al. (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505–2512
Herbst RS, Prager D, Hermann R, et al (2005) TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892–5899
Herbst RS, Giaccone G, Schiller JH, et al (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial–INTACT 2. J Clin Oncol 22:785–794
Giaccone G, Herbst RS, Manegold C, et al (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial–INTACT 1. J Clin Oncol 22:777–784
Gatzemeier U, Pluzanska A, Szczesna A, et al: Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract 7010]. J Clin Oncol 22(suppl 14S):619S, 2004
Herbst RS, Giaccone G, Schiller J, et al (2003) Subset analyses of INTACT results for gefitinib (ZD1839) when combined with platinum-based chemotherapy (CT) for advanced non–small-cell lung cancer (NSCLC) [abstract 2523]. Proc Am Soc Clin Oncol 22:627
Paez JG, Janne PA, Lee JC, et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–14500
Lynch TJ, Bell DW, Sordella R, et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2139–2159
Tsao MS, Sakurada A, Cutz JC, et al (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353:133–144
Pérez-Soler R, Chachoua A, Hammond LA, et al (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238–3247
Fossella FV, DeVore R, Kerr R, et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum containing chemotherapy regimens. J Clin Oncol 18:2354–2362
Shepherd F, Dancey J, Ramlau R, et al (2000) Prospective randomized trial of docetaxel vs. best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095–2013
Hanna N, Shepherd FA, Fossella FV, et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589–1597
Shepard F, Pereira J, Ciulenanu T. (2004) A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer following failure of first line or second line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group trial. J Clin Oncol 2:622s
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lustberg, M.B., Edelman, M.J. Optimal Duration of Chemotherapy in Advanced Non-Small Cell Lung Cancer. Curr. Treat. Options in Oncol. 8, 38–46 (2007). https://doi.org/10.1007/s11864-007-0020-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11864-007-0020-6